Latest

3 stories

Hide weekly roundups

Tuesday, September 1

Polaryx Therapeutics names Will Charlton chief medical officer ahead of Phase 2 trial

Charlton, a pediatric endocrinologist with rare disease drug development experience, joined effective September 1, 2026 as Polaryx prepares to start its SOTERIA trial in the fourth quarter.

SEC filing

Friday, July 31

Polaryx registers Phase 2 basket trial of PLX-200 across four pediatric lysosomal disorders

Trial updategemfibrozil Polaryx Therapeutics, Inc.

Tuesday, July 21

PeoplePolaryx Therapeutics, Inc.

Polaryx Therapeutics' chief medical officer resigns effective immediately

Lisa Bollinger's departure was disclosed in a July 21, 2026 filing, with the company saying it does not expect the move to disrupt existing plans.

SEC filing